Exploring the economics of gene therapy innovation and price
How objective can this be?
TrialSite News article coming up
I’m doing an article with Daniel O’Connor, founder and CEO of TrialSite News. This is their mission and values:
TrialSite’s mission is to drive awareness, introduce transparency, and facilitate engagement among people all over the world, from pharmaceutical professionals and academic researchers to regulators and healthcare professionals along with a wide array of the consuming public.
We value transparency, objectivity, and the scientific method in pursuit of the truth wherever it may lead us.
That’ll do for me!!!
Daniel asked me to critique this paper in the article:
Exploring the economics of gene therapy innovation and price, prepared by Dolon Ltd on behalf of Novartis, the company that brought the first CAR-T therapy (gene therapy) product to market for blood cancers, under the trade name Kymriah.
Our article is targeted at investors, since at the moment they are viewing gene therapy through rose-coloured glasses—this article will dig down into the fact…